Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to developing and commercializing therapeutic assets to treat diseases with unmet medical needs. Aptorum's current drug pipeline includes indications in oncological diseases (including orphan oncology indications) and infectious diseases. The Company has completed two clinical trials in 2021 in respect of ALS-4 (MRSA) and SACT-1 (Neuroblastoma) small molecule drugs and the Company is currently preparing IND applications for the next phases of human clinical trials in the United States. The Company is preparing to launch a dietary supplement for women undergoing menopause and experiencing related symptoms, including osteoporosis. Targeting a global woman’s health supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to generate near-term revenue with significant long-term growth potential.


Lab